AKASA vs Waystar (2026)
Best of breed AI against an incumbent network, and the AI centrality split is the whole story: AKASA graded A because the models are the product, Waystar C because AltitudeAI accelerates a clearinghouse that would sell without it. AKASA is one genuinely model driven engine across the revenue cycle, trained on payer and EHR behaviour so it survives the portal changes that break scripted automation, sold to a reported 650 hospitals. Waystar is scale itself, a network of roughly one million providers processing six billion transactions a year, which is a genuine data advantage its predictive denial tools draw on, and its AI may already be inside the platform a buyer runs. Oversight favours AKASA modestly, expert in the loop at B against Waystar's autonomously generated appeals at C. If your failure mode is wanting the most genuinely model driven automation across the cycle, start with AKASA, confirming integration depth off Epic. If your failure mode is wanting AI inside the network you already run, start with Waystar.
- Genuinely model driven rather than a bundled layer: models trained on payer portal, EHR, and clearinghouse behaviour that tolerate interface change, graded A on AI centrality where Waystar's AltitudeAI accelerates a platform bought for other reasons, graded C.
- One engine across the cycle: coding, documentation integrity, prior authorization, and claims in a single platform graded A on setting coverage, with an expert in the loop design that escalates edge cases.
- Enterprise scale with a flagship reference: more than 650 hospitals and 6,500 outpatient facilities, a reported 43 million training documents, and a Cleveland Clinic collaboration.
- Network scale is the asset: a reported six billion transactions annually for roughly one million providers, touching about half of US patients, graded A on interoperability, a data advantage that feeds its predictive denial scoring.
- The AI may already be in the platform you run: AltitudeCreate drafts appeals from more than 1,100 payer specific templates, AltitudePredict prioritises denials by expected cash value, AltitudeAssist compresses denial prevention to minutes.
- A broad certification set spanning HIPAA, HITRUST, SOC 2, and PCI DSS, graded B on security certifications, where AKASA publishes none located.
This comparison is published by AI Health Index, an independent research platform that compares healthcare AI vendors objectively. AKASA and Waystar are each graded against the same capability taxonomy, from each vendor's own public materials and the regulatory record, under the AI Health Index verification standard. No vendor pays for placement, and no vendor has reviewed this page. How this evidence is graded
Plain facts
| Fact | AKASA | Waystar |
|---|---|---|
| Primary category | RCM & Prior Auth AI | RCM & Prior Auth AI |
| Headquarters | South San Francisco, California | Louisville, Kentucky |
| Website | akasa.com | waystar.com |
Side by Side
Each record in one paragraph
Written to be quoted whole. Each paragraph states what the AI Health Index verified about the vendor, with the caveats attached. Generated from this pair’s live capability grades, so it moves when a grade moves.
The AI Health Index awards AKASA its top capability grade on AI Centrality, Security Certifications and Trust Center and Setting and Specialty Coverage. Set against Waystar, AKASA grades higher on AI Centrality, Autonomy and Oversight Model and AI Governance and Bias Disclosure. Grades reflect evidence the AI Health Index could verify at the last review, so a low grade records disclosure the vendor has not published rather than a capability it has been shown to lack.
Source: AI Health Index, July 2026
The AI Health Index awards Waystar its top capability grade on several axes, including HIPAA and BAA Posture, Security Certifications and Trust Center and FDA and Regulatory Status. Set against AKASA, Waystar grades higher on several axes, including Model Supply Chain Disclosure, HIPAA and BAA Posture and FDA and Regulatory Status. Grades reflect evidence the AI Health Index could verify at the last review, so a low grade records disclosure the vendor has not published rather than a capability it has been shown to lack.
Source: AI Health Index, July 2026
Questions buyers ask
Should we choose AKASA or Waystar?
On the axes where the AI Health Index separates them, AKASA grades higher on AI Centrality, Autonomy and Oversight Model and AI Governance and Bias Disclosure, and Waystar grades higher on several axes, including Model Supply Chain Disclosure, HIPAA and BAA Posture and FDA and Regulatory Status. Waystar leads on the greater share of scored axes, but the split means the decision turns on which constraint is binding rather than on an overall winner.
Where do AKASA and Waystar differ most?
The widest separation the AI Health Index records between AKASA and Waystar is on AI Centrality, where AKASA grades A and Waystar grades C. That axis sits in the AI Capability group, so it should carry the most weight for a buyer whose binding constraint is how much of the work the model itself is trusted to do.
Where do AKASA and Waystar grade the same?
The AI Health Index grades AKASA and Waystar the same on several axes, including Model and Technology Transparency, Clinical and Operational Evidence and AI Safety and PHI Stewardship. Neither holds an advantage the index can evidence on those axes, so they should not carry weight in a selection between these two.
Related comparisons
Other published head to head assessments involving these vendors or their closest peers. The full set for this category is on the RCM & Prior Auth AI page.
Both are partially assessed on this index, roughly six graded axes each, and the contrast is best of breed AI against incumbent bundle. AKASA grades A on AI centrality because the models are the product and genuinely tolerate portal change; Waystar grades C because the revenue cycle platform is what gets bought and the AI rides on top.
On oversight, AKASA states an expert in the loop design but does not publish its confidence threshold, graded B, while Waystar autonomously generates appeal letters with no published review step, graded C. AKASA's EHR depth is uneven off Epic, a diligence item for Cerner and MEDITECH sites. Waystar's scale is a real model advantage, not just marketing reach. A buyer should establish whether Waystar's AltitudeAI is bundled or priced separately. Neither publishes pricing.